ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/Pharmaceutical Intermediate/ALLOC-VAL-CIT-PAB-OH
C22H33N5O6
463.5 g/mol
Pharmaceutical Intermediate

ALLOC-VAL-CIT-PAB-OH

CAS1608127-09-8
Category
Pharmaceutical Intermediate
Compound Class
Peptide
Primary Use
Pharmaceutical Intermediate

ALLOC-VAL-CIT-PAB-OH is a chemical compound used as a pharmaceutical intermediate. It features a peptide-like backbone with specific functional groups, including amide and alcohol moieties, and is employed in the synthesis of conjugated molecules for research and manufacturing purposes.

pharmaceutical intermediateresearch reagent for conjugate synthesis

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing ALLOC-VAL-CIT-PAB-OH?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

SimilarStructure SimilarSimilarity 0.74

Boc-Val-Cit-PABA

CAS870487-09-5

research compound

ReferenceSame Category

Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate

CAS160844-75-7

pharmaceutical intermediate

ReferenceSame Category

2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)aniline

CAS1609394-10-6

pharmaceutical intermediate

ReferenceSame Category

1-Acetyl-5-(2-bromopropyl)-2,3-dihydro-1H-indol-7-amine

CAS160968-95-6

pharmaceutical intermediate

ReferenceSame Category

2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl methanesulfonate

CAS160969-03-9

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

prop-2-enyl N-[(2S)-1-[[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate

InChIKey

VIAGKMZHEWMVCC-ROUUACIJSA-N

SMILES

CC(C)[C@@H](C(=O)N[C@@H](CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)CO)NC(=O)OCC=C

Synonyms (7)
  • ALLOC-VAL-CIT-PAB-OH
  • Alloc-Val-Cit-PAB
  • Aloc-Val-Cit-pAB

Sourcing ALLOC-VAL-CIT-PAB-OH?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→